Almhanna Khaldoun, Pelley Robert J, Thomas Budd G, Davidson Jon, Moore Halle C F
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA.
Anticancer Drugs. 2008 Feb;19(2):217-9. doi: 10.1097/CAD.0b013e3282f2c063.
Subcutaneous implantable venous access devices (IVADs) are commonly used in oncology practice. They facilitate the administration of chemotherapy, fluids and blood products. The incidence of IVAD-related complications is not uncommon, and includes infection, thrombosis and bleeding. IVAD erosion through the skin has been reported secondary to infection or inexperienced handling. We report three cases of IVAD erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy. Anti-vascular endothelial growth factor agents are increasingly used in the treatment of solid tumors. This class of drugs has been associated with delayed wound healing and thromboembolism. To our knowledge, this is the first case series of IVAD erosion through skin, in patients receiving such therapy.
皮下植入式静脉通路装置（IVADs）在肿瘤学实践中常用。它们便于化疗药物、液体和血液制品的给药。IVAD相关并发症的发生率并不罕见，包括感染、血栓形成和出血。据报道，由于感染或操作不熟练，IVAD会发生皮肤侵蚀。我们报告了3例接受抗血管内皮生长因子治疗的患者发生IVAD皮肤侵蚀的病例。抗血管内皮生长因子药物越来越多地用于实体瘤的治疗。这类药物与伤口愈合延迟和血栓栓塞有关。据我们所知，这是接受此类治疗的患者发生IVAD皮肤侵蚀的首个病例系列。
